Immunovant, Inc.
IMVT
$31.46
-$0.15-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.29% | 10.11% | 27.83% | 39.16% | 34.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.63% | 20.23% | 38.21% | 57.81% | 62.15% |
| Operating Income | -21.63% | -20.23% | -38.21% | -57.81% | -62.15% |
| Income Before Tax | -22.39% | -20.51% | -43.29% | -63.88% | -59.58% |
| Income Tax Expenses | -75.84% | 575.70% | 703.58% | 163.51% | 56.97% |
| Earnings from Continuing Operations | -22.17% | -21.29% | -43.86% | -64.12% | -59.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.17% | -21.29% | -43.86% | -64.12% | -59.58% |
| EBIT | -21.63% | -20.23% | -38.21% | -57.81% | -62.15% |
| EBITDA | -21.64% | -20.22% | -38.20% | -57.81% | -62.15% |
| EPS Basic | -1.22% | -2.53% | -27.69% | -48.37% | -44.94% |
| Normalized Basic EPS | -1.31% | -1.87% | -27.21% | -48.21% | -52.74% |
| EPS Diluted | -1.22% | -2.53% | -27.69% | -48.37% | -44.94% |
| Normalized Diluted EPS | -1.31% | -1.87% | -27.21% | -48.21% | -52.74% |
| Average Basic Shares Outstanding | 20.38% | 18.45% | 13.00% | 11.26% | 9.91% |
| Average Diluted Shares Outstanding | 20.38% | 18.45% | 13.00% | 11.26% | 9.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |